Antigen Information

General Information of This Antigen
Antigen ID
TAR0AIJKM
Antigen Name
Hepatocyte growth factor receptor (MET)
Gene Name
MET
Gene ID
4233
Synonym
HGF/SF receptor;Proto-oncogene c-Met;Scatter factor receptor;Tyrosine-protein kinase Met
Sequence
MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEH
HIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMAL
VVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSAL
GAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPE
FRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL
TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRS
AMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEF
TTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFL
LDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGW
CHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK
TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVIT
SISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEF
AVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVH
EAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPV
FKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL
LKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQ
IKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGS
CRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHF
NEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVL
SLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF
VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKF
TTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCW
HPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVD
TRPASFWETS

    Click to Show/Hide
Family
Tyr protein family
Function
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of neuronal precursors, angiogenesis and kidney formation. During skeletal muscle development, it is crucial for the migration of muscle progenitor cells and for the proliferation of secondary myoblasts. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis.

    Click to Show/Hide
Uniprot Entry
MET_HUMAN
HGNC ID
HGNC:7029
KEGG ID
hsa:4233
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
AAJ8D6-Mc-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
 ADC Info 
AAJ8D6-D07-Val-Cit-PAB-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
 ADC Info 
AAJ8D6-PY-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
PY-VC-PABC
 [1]
Anti-MET lgG1
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
LgG1-Mc-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
Anti-MET mAb
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Anti-c-Met IgG-OXA
Oxaliplatin
Human Deoxyribonucleic acid (hDNA)
Dipeptide-p-amidobenzyl alcohol linker
 [2]
Anti-MET mAb Ab-10
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
CN106188293A ADC-1
CN106188293A_ADC-136584232
Undisclosed
CN106188293A_ADC-1LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-2
CN106188293A_ADC-236584232
Undisclosed
CN106188293A_ADC-2LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-3
CN106188293A_ADC-336584232
Undisclosed
CN106188293A_ADC-3LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-4
CN106188293A_ADC-436584232
Undisclosed
CN106188293A_ADC-4LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-9
CN106188293A_ADC-936584232
Undisclosed
CN106188293A_ADC-9LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-12
CN106188293A_ADC-1236584232
Undisclosed
CN106188293A_ADC-12LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
Anti-MET mAb Ab-11
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
CN106188293A ADC-13
CN106188293A_ADC-1336584232
Undisclosed
CN106188293A_ADC-13LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-14
CN106188293A_ADC-1436584232
Undisclosed
CN106188293A_ADC-14LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-15
CN106188293A_ADC-1536584232
Undisclosed
CN106188293A_ADC-15LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
Anti-MET mAb Ab-9
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
CN106188293A ADC-5
CN106188293A_ADC-536584232
Undisclosed
CN106188293A_ADC-5LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-6
CN106188293A_ADC-636584232
Undisclosed
CN106188293A_ADC-6LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-7
CN106188293A_ADC-736584232
Undisclosed
CN106188293A_ADC-7LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-8
CN106188293A_ADC-836584232
Undisclosed
CN106188293A_ADC-8LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-10
CN106188293A_ADC-1036584232
Undisclosed
CN106188293A_ADC-10LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
 ADC Info 
CN106188293A ADC-11
CN106188293A_ADC-1136584232
Undisclosed
CN106188293A_ADC-11LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 [3]
Anti-MET mAb cIRCR201
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
CIRCR201-dPBD
Glucuronide-dPBD
Human Deoxyribonucleic acid (hDNA)
Iso-PEG5-beta-glucuronide
 [4]
Anti-MET mAb hD12
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
HD12-SG3249
PBD dimer SG3249
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 [5]
 ADC Info 
HD12-SG3259
PBD dimer SG3259
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 [5]
 ADC Info 
HD12-SG3315
PBD dimer SG3315
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 [5]
 ADC Info 
HD12-SG3246
PBD dimer SG3246
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 [5]
 ADC Info 
HD12-SG3227
PBD dimer SG3227
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 [5]
cMET A1-8 IgG Fab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
alpha-cMET FDC-Duo5_P1
Duo5
Undisclosed
Undisclosed
 [6]
 ADC Info 
alpha-cMET FDC-Duo5_P2
Duo5
Undisclosed
Undisclosed
 [6]
 ADC Info 
alpha-cMET FDC-Duo5_C
Duo5
Undisclosed
Undisclosed
 [6]
 ADC Info 
alpha-cMET FDC-MMAE_C
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 [6]
 ADC Info 
alpha-cMET ADC-Duo5_P1 (lo DAR)
Duo5
Undisclosed
Undisclosed
 [6]
 ADC Info 
alpha-cMET ADC-Duo5_P1 (hi DAR)
Duo5
Undisclosed
Undisclosed
 [6]
Emibetuzumab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
LY3343544
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 [7]
 ADC Info 
Emibetuzumab-ADC-24-1
Emibetuzumab-ADC-24-1 payload
Undisclosed
Emibetuzumab-ADC-24-1 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-2
Emibetuzumab-ADC-24-2 payload
Undisclosed
Emibetuzumab-ADC-24-2 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-3
Emibetuzumab-ADC-24-3 payload
Undisclosed
Emibetuzumab-ADC-24-3 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-4
Emibetuzumab-ADC-24-4 payload
Undisclosed
Emibetuzumab-ADC-24-4 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-5
Emibetuzumab-ADC-24-5 payload
Undisclosed
Emibetuzumab-ADC-24-5 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-6
Emibetuzumab-ADC-24-6 payload
Undisclosed
Emibetuzumab-ADC-24-6 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-7
Emibetuzumab-ADC-24-7 payload
Undisclosed
Emibetuzumab-ADC-24-7 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-8
Emibetuzumab-ADC-24-8 payload
Undisclosed
Emibetuzumab-ADC-24-8 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-9
Emibetuzumab-ADC-24-9 payload
Undisclosed
Emibetuzumab-ADC-24-9 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-10
Emibetuzumab-ADC-24-10 payload
Undisclosed
Emibetuzumab-ADC-24-10 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-11
Emibetuzumab-ADC-24-11 payload
Undisclosed
Emibetuzumab-ADC-24-11 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-12
Emibetuzumab-ADC-24-12 payload
Undisclosed
Emibetuzumab-ADC-24-12 linker
 [8]
 ADC Info 
Emibetuzumab-ADC-24-13
Emibetuzumab-ADC-24-13 payload
Undisclosed
Emibetuzumab-ADC-24-13 linker
 [8]
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
HAV ADC
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 [9]
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
LAV ADC
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 [9]
PCM-MET01
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
PCM-MET01-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [10]
SCAc-Met (1)xSCAc-Met (2)
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
CN117337196A Compound94
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA)
 [11]
STI-D0606
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
C-met monoclonal antibody-drug conjugate
Mertansine DM1
Microtubule (MT)
Undisclosed
 [12]
Telisotuzumab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
ABT-700 (S238C)-PBD
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala
 [13]
 ADC Info 
ABT-700-Mc-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
 ADC Info 
37307297 ADC 15
FD-1
Undisclosed
Undisclosed
 [14]
 ADC Info 
37307297 ADC 16
FD-1
Undisclosed
Undisclosed
 [14]
 ADC Info 
37307297 ADC 17
FD-1
Undisclosed
Undisclosed
 [14]
 ADC Info 
37307297 ADC 18
FD-1
Undisclosed
Undisclosed
 [14]
 ADC Info 
37307297 ADC 19
FD-2
Undisclosed
Undisclosed
 [14]
 ADC Info 
37307297 ADC 20
FD-3
Undisclosed
Undisclosed
 [14]
Undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
SAB-Y14
Undisclosed
Undisclosed
Undisclosed
 [15]
 ADC Info 
Hu-cMet 27Gv1.3 Hinge-L-DM21
Undisclosed
Undisclosed
Undisclosed
 [16]
 ADC Info 
C-MET 0174
Undisclosed
Undisclosed
Undisclosed
 [17]
 ADC Info 
APS-3010
Undisclosed
Undisclosed
Undisclosed
 [18]
undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
30kmPEG (SCAc-Met (1)xSCAc-Met (1))-2 (Val-Cit-PAB-DEA-SN38)
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Undisclosed
 [19]
References
Ref 1 Anti-c-met antibody-drug conjugate and applications thereof; 2022-03-10.
Ref 2 High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Front Oncol. 2019 Aug 2;9:717. doi: 10.3389/fonc.2019.00717. eCollection 2019.
Ref 3 Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof.
Ref 4 cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors. ACS Omega. 2020 Sep 29;5(40):25798-25809. doi: 10.1021/acsomega.0c03102.
Ref 5 TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. doi: 10.1002/1878-0261.12600. Epub 2019 Dec 3.
Ref 6 Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET
Ref 7 A novel molecule with profound tumor killing activity. Cancer Res (2019) 79 (13_Supplement): 353.
Ref 8 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.
Ref 9 Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals
Ref 10 MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res. 2020 Sep 22;39(1):198. doi: 10.1186/s13046-020-01711-x.
Ref 11 PEGylated antibody hydroxyl-bearing drug conjugates
Ref 12 Introduction to basic information on ADC drug C-met monoclonal antibody-drug conjugate
Ref 13 ANTI-cMet antibody drug conjugates and methods for their use; 2017-11-23.
Ref 14 Structure-Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody-Drug Conjugate Payloads
Ref 15 Syntab therapeutics biotechnology company product pipeline
Ref 16 Preclinical evaluation of a new, non-agonist ADC targeting MET-amplified tumors with a peptide-linked maytansinoid. Cancer Res (2019) 79 (13_Supplement): 4817.
Ref 17 c-Met Antibody Drug Conjugate.
Ref 18 Introduction to basic information on ADC drug APS-3010.
Ref 19 PEGylated antibody hydroxyl-bearing drug conjugates